PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 15, 2026Medicina0 citationsOpen Access

Myocardial Viability and Ischaemia in Chronic Total Occlusion

View Full Paper
ZMZia MehmoodPSPreethi SureshRLRui Li

Key Points

  • This research aims to assess myocardial viability and ischaemia in patients with chronic total occlusion using advanced imaging techniques.
  • Fifty-six patients with angiographically confirmed chronic total occlusion underwent stress perfusion cardiovascular magnetic resonance.
  • Late gadolinium enhancement was utilized to assess myocardial function and scar burden.
  • Viability and ischaemia were quantitatively compared across different subgroups.
  • 27% of patients had no myocardial viability in chronic total occlusion.
  • 66% of patients with viable myocardium demonstrated reversible ischaemia.
  • Viable myocardium was associated with higher left ventricular stroke volumes and lower scar mass and percentage compared to non-viable myocardium.

Abstract

Background and Objectives: Chronic total occlusion (CTO) affects 30% of patients undergoing coronary angiography rendering poorer outcomes. While percutaneous coronary intervention (PCI) can be technically successful, RCTs show no survival benefit. Cardiovascular Magnetic Resonance (CMR) provides comprehensive myocardial phenotyping, offering prognostic insights in this high-risk cohort. Materials and Methods: Fifty-six patients with angiographically confirmed CTO underwent stress perfusion CMR with late gadolinium enhancement. Myocardial function, ischaemia and scar burden were quantified and compared across CTO territory and viability subgroups. Results: In patients with CTO, 27% of patients (15/56) had no viability. In patients with viable myocardium, 66% (27/41) demonstrated reversible ischaemia. Viable myocardium was associated with significantly higher LV stroke volumes (93.6 ± 20.1 mL vs. 80.9 ± 18.4 mL, p = 0.039), along with lower LV scar mass (18.7 ± 13.5g vs. 32.3 ± 12.8g; p = 0.002) and scar percentage (14.9 ± 8.3% vs. 25.9 ± 7.5%; p = 0.001). Viable myocardium showed more ischaemia both globally (11.6 ± 14.3g vs. 0.2 ± 9.3g; p = 0.005) and within the CTO territory (10.3 ± 10.3% vs. 2.3 ± 2.7%; p = 0.01). Non-viable myocardium was associated with significantly higher CTO-territory scar mass (9.4 ± 6.5 g vs. 5.1 ± 6.9 g; p = 0.046) and scar percentage (21.8 ± 13.3% vs. 11.7 ± 12.8%; p = 0.01), indicating extensive fibrosis. A scar burden threshold of 11.18% in CTO territory predicted non-viability with 80% sensitivity and 65.85% specificity (AUC = 0.701 95% CI 0.54–0.87, p = 0.019). Conclusions: Among CTO patients, 27% harbour no viability, while patients with viable myocardium typically exhibit reversible ischaemia—representing a phenotype with preserved viability and inducible ischaemia. These findings support the use of multiparametric CMR to phenotype CTO territories prior to considering CTO-PCI.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Mehmood et al. (2026) studied this question.

synapsesocial.com/papers/69b606af83145bc643d1ce3bhttps://doi.org/10.3390/medicina62030540
Ask AI
Helpful
Bookmark
Share
View Full Paper